Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:35:17 17/07/2024 BST			5-day change	1st Jan Change
111.2 ^EUR	+0.36%		+1.83%	+3.06%

07-11	CAC40: maintains gains after reassuring US inflation figures	CF
07-11	CAC40: rise without volume, W-Street at its zenith but falls back	CF

IPSEN : Buy back programme Art 5 of MAR Week 23 2024

June 11, 2024 at 05:04 pm

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

11 Jun 2024 18:00 CEST

Issuer

IPSEN

Aggregatedpresentationbydayandbymarket

Statement of transactions in own shares from June 3 to June 7, 2024

Name of issuer	Identificationcodeof issuer (Legal Entity Identifier)	Day of transaction	Identificationcodeof financial instrument	Aggregated daily volume (in number of shares)	Daily weighted average price of the purchased shares *	Market (MIC Code)
IPSEN	549300M6SGDPB4Z94P11	03/06/2024	FR0010259150	3 100	120,9943	XPAR
IPSEN	549300M6SGDPB4Z94P11	04/06/2024	FR0010259150	3 100	121,5713	XPAR
IPSEN	549300M6SGDPB4Z94P11	05/06/2024	FR0010259150	3 100	122,2187	XPAR
IPSEN	549300M6SGDPB4Z94P11	06/06/2024	FR0010259150	3 500	122,5593	XPAR
IPSEN	549300M6SGDPB4Z94P11	07/06/2024	FR0010259150	5 000	123,1718	XPAR
			TOTAL	17 800	122,2274
				17 800

Attachment

EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 23_2024

Source

Ipsen Pharma

Provider

GlobeNewswire

Company Name

IPSEN

ISIN

FR0010259150

Symbol

IPN

Market

Euronext

Attachments

Original Link
Permalink

Disclaimer

Ipsen SA published this content on 11 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2024 16:03:05 UTC.

Latest news about Ipsen

CAC40: maintains gains after reassuring US inflation figures	07-11	CF
CAC40: rise without volume, W-Street at its zenith but falls back	07-11	CF
CAC40: over 7600pts before US inflation figures	07-11	CF
Ipsen: worldwide licensing agreement with Foreseen	07-11	CF
Ipsen, Foreseen Biotechnology Ink Exclusive Global Licensing Deal for Antibody-drug Conjugate	07-11	MT
Markets Powered by Alternating Current	07-10
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China	07-05	MT
Ipsen Expands Partnership with Exelixis for Cabometyx	07-02	MT
Ipsen extends collaboration with Exelixis	07-02	CF
IPSEN : UBS remains positive ahead of quarterly results	06-26	CF
Ipsen: share price soars, UBS confirms its recommendation	06-12	CF
IPSEN : UBS remains Buy after FDA approval	06-12	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	06-11	CI
Ipsen: FDA grants approval for treatment	06-11	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	06-11	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	06-10	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	06-10	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	06-10	RE
US FDA approves Genfit and Ipsen's liver disease drug	06-10	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	06-07	MT
Ipsen: research partnership with Marengo extended	06-07	CF
Ipsen Hires New Chief Corporate Affairs Officer	06-06	MT
Ipsen: new Chief Corporate Affairs Officer	06-06	CF
Ipsen: new positive data in PBC	06-05	CF
Ipsen: mandate to an ISP for share buybacks	06-03	CF

Chart Ipsen

Duration

Period

More charts

Company Profile

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

23/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 03:50 pm

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.2 EUR

Average target price

127.3 EUR

Spread / Average Target

+14.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+3.06%	9.96B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

IPSEN : Buy back programme Art 5 of MAR Week 23 2024

EPS Revisions